Padma Shri for senior oncologist
Read more below
- Published 26.01.12
|Oncologist Dr Jitendra Kumar Singh. Picture by Deepak Kumar|
Patna, Jan. 25: Senior oncologist Dr Jitendra Kumar Singh will be the sole recipient of Padma Shri from the state this year.
Sixty-year-old Singh is at present the director of Mahavir Cancer Sansthan. His name was announced today, along with the other awardees, in New Delhi on the eve of the 63rd Republic Day.
The oncologist told The Telegraph that this was a moment of great personal pride and happiness for him.
“The news came as a pleasant surprise to me. My contribution to the field of medicine and cancer treatment has been recognised by the Government of India, and I have been given the fourth highest civilian award. This means increased responsibility and accountability for me. It will also encourage me to surge ahead,” said a visibly elated Singh.
President Pratibha Patil has approved the names of 109 awardees, including five for Padma Vibhushan, 27 for Padma Bhushan and 77 for Padma Shri.
The President will confer the awards in March or April this year in an annual function held at the Rashtrapati Bhavan.
Singh has been associated with the Mahavir Cancer Sansthan for the past 11 years. He has also been actively engaged in cancer-awareness programmes in the state.
Trained at Tata Memorial Hospital, Mumbai, Singh first worked at the radium institute of Patna Medical College and Hospital for 14 years. He also worked at Darbhanga Medical College and Hospital as an associate professor.
At present, he serves as an examiner in the Diplomate of National Board, and supervises postgraduate courses at several medical colleges. Singh, who was born in Bhagalpur district, is also the national president of two major associations of cancer management in the country — Indian Brachytherapy Society and Indian Hyperthermic Oncological Medicine.
He is also the author of 73 articles in national and international journals. Singh has also served as the principal investigator in 22 national and international clinical trials of cancer medicines.